<DOC>
	<DOC>NCT00967681</DOC>
	<brief_summary>The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.</brief_summary>
	<brief_title>Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Fibrocystic Breast Disease</mesh_term>
	<criteria>Patients with clinical and ultrasonographic confirmation of breast fibrocystic disease. Patients older than 20 years. Female patients. Informed consent. Presents of another disease not well controlled. Pregnant women or lactating. Patient which are receiving another products from other investigations trials.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>